BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu L, Zhang J, Guo X, Li Z, Zhang P. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma. Cancer Epidemiol. 2014;38:408-413. [PMID: 24923856 DOI: 10.1016/j.canep.2014.05.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Sun L, Bian G, Meng Z, Dang G, Shi D, Mi S. MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression. PLoS One 2015;10:e0124428. [PMID: 25961751 DOI: 10.1371/journal.pone.0124428] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
2 Yang J, Han S, Huang W, Chen T, Liu Y, Pan S, Li S. A meta-analysis of microRNA expression in liver cancer. PLoS One 2014;9:e114533. [PMID: 25490558 DOI: 10.1371/journal.pone.0114533] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
3 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
4 Wang Y, Wang N, Zeng X, Sun J, Wang G, Xu H, Zhao W. MicroRNA-335 and its target Rock1 synergistically influence tumor progression and prognosis in osteosarcoma. Oncol Lett 2017;13:3057-65. [PMID: 28521412 DOI: 10.3892/ol.2017.5818] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
5 George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 2015;35:63-74. [PMID: 25632936 DOI: 10.1055/s-0034-1397350] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
6 Fu F, Wu D, Qian C. The MicroRNA-224 Inhibitor Prevents Neuronal Apoptosis via Targeting Spastic Paraplegia 7 After Cerebral Ischemia. J Mol Neurosci 2016;59:421-9. [PMID: 27165196 DOI: 10.1007/s12031-016-0769-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
7 Zeng Z, Dong J, Li Y, Dong Z, Liu Z, Huang J, Wang Y, Zhen Y, Yinying Lu. The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:3067-71. [DOI: 10.1080/21691401.2019.1640228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ, Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L, Chen YP. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance. Oncotarget 2015;6:25093-108. [PMID: 26231037 DOI: 10.18632/oncotarget.4437] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
9 Zhang Y, Huang W, Ran Y, Xiong Y, Zhong Z, Fan X, Wang Z, Ye Q. miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumour Biol 2015;36:8309-16. [PMID: 26002580 DOI: 10.1007/s13277-015-3582-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
10 Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol 2016;22:9069-95. [PMID: 27895396 DOI: 10.3748/wjg.v22.i41.9069] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 66] [Article Influence: 18.5] [Reference Citation Analysis]
11 He S, Zhang DC, Wei C. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. Clin Res Hepatol Gastroenterol. 2015;39:426-434. [PMID: 25746139 DOI: 10.1016/j.clinre.2015.01.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
12 Lu W, Yang C, Du P, Zhang JL, Zhang JC. Expression tendency and prognostic value of TCF21 in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2019;47:1466-70. [PMID: 31014118 DOI: 10.1080/21691401.2019.1601102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG, Fiorentino E, Rolfo C, Bazan V, Di Marco V, Russo A. HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016;97:312-21. [PMID: 26603462 DOI: 10.1016/j.critrevonc.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
14 Liu H, Li W, Chen C, Pei Y, Long X. MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma. Tumour Biol. 2015;36:6313-6319. [PMID: 25804796 DOI: 10.1007/s13277-015-3317-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
15 Cavedon E, Barollo S, Bertazza L, Pennelli G, Galuppini F, Watutantrige-Fernando S, Censi S, Iacobone M, Benna C, Vianello F, Zovato S, Nacamulli D, Mian C. Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma. Int J Endocrinol 2017;2017:4915736. [PMID: 28676824 DOI: 10.1155/2017/4915736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M, McCubrey JA. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets 2019;23:915-29. [PMID: 31657972 DOI: 10.1080/14728222.2019.1685501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
17 Cui R, Kim T, Fassan M, Meng W, Sun HL, Jeon YJ, Vicentini C, Tili E, Peng Y, Scarpa A, Liang G, Zhang YK, Chakravarti A, Croce CM. MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7. Oncotarget 2015;6:21802-15. [PMID: 26307684 DOI: 10.18632/oncotarget.5224] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
18 Zhang Y, Guo CC, Guan DH, Yang CH, Jiang YH. Prognostic Value of microRNA-224 in Various Cancers: A Meta-analysis. Arch Med Res 2017;48:472-82. [PMID: 29133193 DOI: 10.1016/j.arcmed.2017.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Yu LM, Wang WW, Qi R, Leng TG, Zhang XL. MicroRNA-224 inhibition prevents progression of cervical carcinoma by targeting PTX3. J Cell Biochem. 2018;119:10278-10290. [PMID: 30129088 DOI: 10.1002/jcb.27370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Li S, Zhang J, Zhao Y, Wang F, Chen Y, Fei X. miR-224 enhances invasion and metastasis by targeting HOXD10 in non-small cell lung cancer cells. Oncol Lett 2018;15:7069-75. [PMID: 29731873 DOI: 10.3892/ol.2018.8245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]